Andrade Robert 4

What Happened

• Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals, reported an acquisition (award/release) of 1,191 shares on 2026-02-28. The reported acquisition price was $0.00, so the immediate cash value shown on the Form 4 is $0.
• This was not an open-market purchase or sale but a release/award of previously granted restricted shares (see footnote).

Key Details

• Transaction date: 2026-02-28; Form 4 filed: 2026-03-03 (appears timely).
• Transaction type/code: A — Grant/award or other acquisition; Price per share: $0.00; Shares acquired: 1,191.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: "Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024."
• No 10b5-1 plan, tax withholding, or sale reported in this filing.

Context

• These shares represent restricted-forfeitable shares that became vested or were otherwise released from restriction — a common form of compensation for executives. Because the shares were not purchased on the open market, this report does not necessarily signal new buying interest by the insider.
• Such awards are typically part of compensation/vesting schedules and may have tax implications for the insider; they are informational for investors but do not by themselves indicate a change in insider sentiment.